Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis
Total article views: 945 (including HTML, PDF, and XML)Cumulative views and downloads (calculated since 27 Jul 2022)Views and downloads (calculated since 27 Jul 2022)
Viewed (geographical distribution)
Total article views: 897 (including HTML, PDF, and XML) Thereof 897 with geography defined and 0 with unknown origin.
3 citations as recorded by crossref.
- The Lysin Exebacase Has a Low Propensity for Resistance Development in Staphylococcus aureus and Suppresses the Emergence of Resistance to Antistaphylococcal Antibiotics J. Oh et al. 10.1128/spectrum.05261-22
- Lysins – a new armamentarium for the treatment of bone and joint infections? P. Sendi & T. Ferry 10.5194/jbji-7-187-2022
- Cost-effectiveness of a bone substitute delivering gentamicin in the treatment of chronic osteomyelitis of long bones: Protocol for the CONVICTION randomized multicenter study H. Serrier et al. 10.3389/fmed.2023.1116711
Latest update: 25 Sep 2023